Kairos Pharma’s (NYSEAMERICAN:KAPA – Get Free Report) lock-up period is set to expire on Monday, March 17th. Kairos Pharma had issued 1,550,000 shares in its initial public offering on September 16th. The total size of the offering was $6,200,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
Analysts Set New Price Targets
Separately, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a report on Wednesday, February 26th.
Read Our Latest Report on KAPA
Kairos Pharma Price Performance
About Kairos Pharma
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
Read More
- Five stocks we like better than Kairos Pharma
- What Are Dividends? Buy the Best Dividend Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Profit From Value Investing
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Where Do I Find 52-Week Highs and Lows?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
